RE:BTIGVery, very nice... $8US or just over $10Cnd.
Looks like US analysts are warming up to IMV. The fact that Shrader thinks DPX "flies in the face of modern immunology" goes to show how little recognition IMV tech has out there. Love it.
Shrader is a solid analyst with over 20 years experience. PHD, Yale, pharma, analyst exp. he has it all. BTG is a big world wide institutional firm.
I like this win from IMV as much as WFargo or maybe more. Well done Mr. Ors.
Furthermore, they are having a health conference in Feb. in NY. Coincidence???
Things are unfolding as I predicted 4-5 months ago when I was urging to back up the truck at $3, while everyone was throwing in the towel on IMV and mngmt.
Despite all the naysayers, EVERYTHING is unfolding as per my predictions and analysis.
If Ovarian data turns out as I expect it will than my $20 initial target is going to come faster than a keystroke on the keyboard...
Too bad I hold close to .5% of the company :)
Here is the conference: BTIG announced today that the "BTIG Targeted Therapeutics Conference" will take place on Monday, February 24, 2020 in New York. Here is the Bio: Dr. Shrader has more than 20 years of biotechnology equity research experience. Prior to BTIG, he was the Vice President of Strategy and Communications at Intrexon Corporation. Previously, Dr. Shrader was a Biotechnology Research Analyst at Stifel and Bank of Montreal Capital Markets. He was also the Director of Strategic Corporate Partnerships at Yale University, and a Biochemistry faculty member at the Albert Einstein College of Medicine. Dr. Shrader earned a BA from Johns Hopkins University, a PhD from Yale University and was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology. He is also a CFA charterholder.